| Literature DB >> 35815211 |
Min Yang1, Chao Wu1,2, Tianxi Zhang1, Lei Shi1, Jian Li1,3, Hongbao Liang1,4, Xuzhen Lv1, Fengtang Jing1, Lu Qin1, Tianlun Zhao1, Chenxi Wang1, Guangxu Liu1, Shuai Feng1, Feng Li1.
Abstract
Chicoric acid has been widely used in food, medicine, animal husbandry, and other commercial products because of its significant pharmacological activities. However, the shortage of chicoric acid limits its further development and utilization. Currently, Echinacea purpurea (L.) Moench serves as the primary natural resource of chicoric acid, while other sources of it are poorly known. Extracting chicoric acid from plants is the most common approach. Meanwhile, chicoric acid levels vary in different plants as well as in the same plant from different areas and different medicinal parts, and different extraction methods. We comprehensively reviewed the information regarding the sources of chicoric acid from plant extracts, its chemical synthesis, biosynthesis, and bioactive effects.Entities:
Keywords: bioactive effects; biosynthesis; chemical synthesis; chicoric acid; content detection; natural occurrence
Year: 2022 PMID: 35815211 PMCID: PMC9262330 DOI: 10.3389/fchem.2022.888673
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.545
FIGURE 1Three optical structures of chicoric acid.
FIGURE 2Chemical structure, bioactive effects, and acquisition pathways of chicoric acid.
Plants that are the principal sources of chicoric acid.
| Plant names | Family | Genus | Resource distribution | Morphological classification | Plant parts | References |
|---|---|---|---|---|---|---|
|
| Asteraceae |
| North America and China | Perennial herb | Aerial parts and roots |
|
|
| Asteraceae |
| East Asia and Southeast Asia | Perennial herb | Leaves |
|
|
| Asteraceae |
| Mediterranean region and Southwest Asia | Perennial herb | Aerial parts and roots |
|
|
| Asteraceae |
| Temperate areas | Annual or biennial plant | Lettuce head and leaves |
|
|
| Asteraceae |
| Temperate areas | Perennial herb | Aerial parts and roots |
|
|
| Asteraceae |
| Northwest and South of China | Annual or perennial herb | Aerial parts and roots |
|
|
| Asteraceae |
| Northeast, North, Central, and South China | Annual or biennial herb | Leaves |
|
|
| Asteraceae |
| North, South, and East China | Perennial herb | Aerial parts and roots |
|
|
| Asteraceae |
| Europe and China | Perennial herb | Flowering heads |
|
|
| Asteraceae |
| China | Perennial plant | Aerial parts |
|
|
| Lamiaceae |
| China | Small shrub | Leaves |
|
|
| Lamiaceae |
| India, Malaysia, China, Australia, and the Pacific area | Perennial herb | Leaves |
|
|
| Alismataceae |
| Central America and South Brazil | Perennial marsh plant | Leaves |
|
|
| Leguminosae |
| Tropics and Subtropics | Annual plant | Leaf terminals |
|
|
| Equisetaceae |
| Europe, Asia, and North America | Perennial herb | Sprouts and gametophytes |
|
|
| Lygodiaceae |
| Australia and China | Perennial climbing plant | Frond |
|
|
| Potamogetonaceae |
| Temperate northern hemisphere | Perennial herb | Leaves |
|
Comparison of chicoric acid levels in Echinacea purpurea (L.) Moench.
| Extraction methods | Medicinal origin | Medicinal parts | Extraction conditions | Yield of chicoric acid (%) | References |
|---|---|---|---|---|---|
| Reflux extraction | Shaanxi | Dried aboveground parts | Extraction was performed 3 times with 1.5 h each time | 1.03 |
|
| Xinjiang | All dried grasses | 15 times; 40% ethanol, 3 times, 2 h each time | 0.55 |
| |
| The extraction temperature was 90°C | |||||
| Guangdong | All dried grasses | 8 times; 80% ethanol, 3 times, 1 h each time | 1.09 |
| |
| Hebei | Dried flowers | 20 times; 20% ethanol, 2 times, 2 h each time, extraction temperature was 90°C | 0.75 |
| |
| Shandong | Dried flowers | 20 times; 60% ethanol, 2 times, 2 h each time, extraction temperature of 70°C | 2.30 |
| |
| Ultrasonication extraction | Anhui | All dried grasses | 8 times; 55% ethanol was extracted twice, 45 min each | 1.22 |
|
| Beijing | Dried roots, stems, leaves, flowers, aboveground parts | 125 times; methanol–0.5% phosphoric acid (4:1) solution was extracted by ultrasound for 40 min | 0.90 (root) |
| |
| 0.43 (stem) | |||||
| 1.84 (leaf) | |||||
| 2.15 (flower) | |||||
| 1.05 (overground part) | |||||
| Shandong | Dried roots, stems, leaves, flowers | 125 times; 70% methanol, ultrasound 30 min | 1.28 (root) |
| |
| 0.36 (stem) | |||||
| 2.32 (leaf) | |||||
| 2.11 (flower) | |||||
| Shandong | Dried aboveground parts | 62.5 times; 70% methanol was extracted by ultrasonography for 3 times, 10 min each | 2.02 |
| |
| Guangdong | Dried roots, stems, leaves, flowers, whole grasses | 62.5 times; methanol–0.5% phosphoric acid aqueous solution (4:1) was extracted by ultrasound for 60 min | 1.21 (root) |
| |
| 0.07 (stem) | |||||
| 0.56 (leaf) | |||||
| 0.25 (flower) | |||||
| 0.33 (whole herb) | |||||
| Ultrasonic microwave co-extraction method | Tianjin | Fresh roots | 25 times; 50% ethanol, ultrasound for 90 s without microwave power; the extraction power was 300 W and the extraction time was 660 s | 0.02 |
|
| Spray extraction | Shaanxi | All dried grasses | Spray 4 times 70% ethanol at 20 kg pressure for 3 min | 0.53 |
|
| Supercritical carbon dioxide extraction method | Guangdong | Dried flowers | CO2 was extracted with 40% ethanol entrainment at a flow rate of 25 kg/hand a pressure of 30 MPa for 2 h at 60°C | 1.06 |
|
Comparison of the content of chicoric acid in different plants.
| Herbs | Medicinal origin | Medicinal parts | Extraction methods | Extraction conditions | Yield of chicoric acid (%) | References |
|---|---|---|---|---|---|---|
|
| Xinjiang | Dried stem | Ultrasonication extraction | 21 times; 50% ethanol, ultrasound at 60°C for 50 min (180 W) | 0.15 |
|
| Jiangsu | Dried overground part | Ultrasonication extraction | 12 times; 54% ethanol, ultrasound 30 min (40 w) | 0.15 |
| |
| Jiangsu | Dried overground part | Reflux extraction | 24 times; 54% ethanol was refluxed at 90°C for 1 h | 0.15 |
| |
| Netherlands | Dried overground part | Dried overground part | Reflux of 60 times 70% methanol at 60°C for 1 h | 0.88 |
| |
|
| Shanxi | Dried overground part | Reflux extraction | 50 times; 70% ethanol heated reflux extraction 1 h | 0.77–1.14 |
|
|
| Shanxi | Dried overground part | Reflux extraction | 50 times; 70% ethanol heated reflux extraction 1 h | 0.34–2.69 |
|
|
| Jiangsu | Dried leaves | Ultrasonication extraction | Ultrasonic extraction with 100 times 80% ethanol solution at 45°C for 70 min | 2.61 |
|
|
| Jiangsu | Dried leaves | Ultrasonication extraction | Ultrasonic extraction with 100 times 80% ethanol solution at 45°C for 70 min | 1.50 |
|
FIGURE 3Chemical synthesis pathway 1 of chicoric acid.
FIGURE 4Chemical synthesis pathway 2 of chicoric acid.
FIGURE 5Chemical synthesis pathway 3 of chicoric acid.
FIGURE 6Chemical synthesis pathway 4 of chicoric acid.
FIGURE 7Chemical synthesis pathway 5 of chicoric acid.
FIGURE 8Chemical synthesis pathway 6 of chicoric acid.
FIGURE 9Biosynthetic pathway of chicoric acid.
In vitro effects of chicoric acid in the treatment of various disorders.
| Disorders | Models | Dose (μM) | Duration (h) | Effects | Suggested mechanisms | References |
|---|---|---|---|---|---|---|
| Diabetes | HUVECs | 100 | 24 | ↓ cell apoptosis | (+) the AMPK signaling pathway; ↓ Iκ-Bα; ↓ NF-κB; ↓ iNOS; ↓ IL-1β; ↓ p-eNOS |
|
| ↓ p65 NF-κB nuclear translocation | ||||||
| ↓ oxidative/nitrative stresses | ||||||
| PC-12 cells | 10 and 20 | 24 | ↓ misfolding; ↓ fibrillation of hIAPP; ↓ aggregation | ↓ Cytotoxicity; ↑ biocompatibility |
| |
| Lipid metabolism | HepG2 human hepatoma | 100 and 200 | 24 | ↓ lipid accumulation | (−) SREBP-1/FAS signaling pathways; (+) PPARa/UCP2 signaling pathways |
|
| HepG2 human hepatoma | 10 and 20 | 24 | ↓ lipid accumulation; ↓ oxidative stress; ↓ inflammation | ↑ AMPK; ↑ Nrf2; ↓ NF-κB |
| |
| Inflammation | PBMCs (T2DM patients) | 50 | 6 | ↓ inflammation | ↓ IL-6; ↑ SIRT1; ↑ pAMPK |
|
| SH-SY5Y cells | 80 | 12 | (−) inflammatory factor release; ↑ mitochondrial function and energy metabolism | ↑ PGC-1α; ↑ SIRT1; ↑ pAMPK |
| |
| Gastric function | Human gastric cancer cell | 20 | 48 | (−) apoptosis in gastric cancer cells; ↓ cell viability | ↑ p70S6 kinase; ↑ AMPK; ↑ PERK; ↑ ATF4 |
|
↑, increase; ↓, decrease; (+), active; (−), inhibit; N/A, not available; HUVECs, human umbilical vein endothelial cells; NF-κB, nuclear factor-kappa B; Iκ-Bα, inhibitor kappa B alpha; iNOS, inducible nitric oxide synthase; IL-1β, interleukin-1 beta; hIAPP, human islet amyloid polypeptide; AMPK, AMP-activated protein kinase; Nrf2, nuclear factor–erythroid 2 related factor 2; PBMCs, peripheral blood mononuclear cells; T2DM, type 2 diabetes mellitus; IL6, interleukin 6; PGC-1α, peroxisome proliferator–activated receptor-γ coactivator-1α; SIRT1, silent information regulator type 1; pAMPK, phospho-AMP–activated protein kinase; PERK, protein kinase RNA-like ER kinase; ATF4, activating transcription factors 4.
In vivo effects of chicoric acid in the treatment of various disorders.
| Disorders | Species (sex) | Models | Dose (mg/kg/d) | Duration (days) | Effects | Suggested mechanisms | References |
|---|---|---|---|---|---|---|---|
| Brain function | C57BL/6 mice (M) | Parkinson's disease (MPTP) | 40, p.o. | 12 | ↑ immunological response | ↑ BDNF; ↑ DA; ↑ 5-HT |
|
| Chicken embryo (N/A) | Neurotoxicity (TH) | 100 µg/60 g (air cell injection) | 19 | ↑ Antioxidant; ↑ anti-inflammatory; ↑ genoprotective; ↑ antiapoptotic; ↓ NO; ↓ MPO | ↓ TNF-α; ↓ IL-1β; ↓ CASP3; ↓ BCL-2; ↓ NF-κB1 |
| |
| Liver function | C57BL/6 mice (M) | Acute liver injury (LPS + d-GalN) | 50, p.o. | 1 | ↓ Hepatic injury; ↓ inflammation | (+) Nrf2 pathway; ↓ MAPKs; ↓ NF-κB; ↓ ALT; ↓ AST; ↑ AMPK |
|
| Wistar rats (M) | Liver injury (methotrexate) | 25 and 50, p.o. | 19 | ↓ Hepatic injury; ↓ inflammation; ↓ oxidative stress | (+) Nrf2/HO-1 signaling and PPARγ; ↑ Nrf2; ↑ HO-1; ↑ NQO-1; ↑ PPARγ; ↑ BCL-2; ↓ Bax; ↓ cytochrome c; ↓ caspase-3 |
| |
| C57BL/6 mice (M) | Nonalcoholic fatty liver (high-fat diet) | 15 or 30, p.o. | 63 | ↓ lipid accumulation; ↓ oxidative stress; ↓ inflammation | ↑ SOD; ↓ ROS; ↑ AMPK; ↑ Nrf2; ↓ NF-κB |
| |
| Aging |
| Lifespan extension (chicoric acid) | 25 and 50, p.o. | 12 | ↑ Oxidative stress resistance; ↓ ROS; ↓ pumping rate; ↓locomotive activity | In part through regulation AAK-2 and SKN-1 |
|
| Kidney function | Wistar rats (M) | Acute kidney injury (methotrexate) | 25 and 50, i.p. | 15 | (−) apoptosis; ↑ antioxidant defenses | ↓ NF-κB; ↓ p65; ↓ NLRP3; ↓ caspase-1; ↓ IL-1β; ↓ caspase-3; ↑ BCL-2 |
|
| Lung function | BALB/c mice (M) | Acute lung injury (lipopolysaccharide) | 20 or 40, i.p. | 12 | ↓ protein leakage; ↓ lung wet/dry ratio; ↑ antioxidant defenses | ↓ MAPK; ↑ SOD; ↑ HO-1; ↑ Nrf2;↓ MPO |
|
M, male; F, female; ↑, increase; ↓, decrease; (+), active; (−), inhibit; p.o., per os (oral administration); i.p., intraperitoneal injection; N/A, not available; BDNF, brain-derived neurotrophic factor; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; DA, dopamine; 5-HT, 5-hydroxyindoleacetic acid; TH, thiacloprid; TNF-α, tumor necrosis factor-alpha; NO, nitric oxide; MPO, myeloperoxidase; CASP3, apoptosis-related cysteine peptidase; BCL-2, B-cell CLL/lymphoma 2; LPS, lipopolysaccharide; d-GalN, d-galactosamine; MAPKs, mitogen-activated protein kinases; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AMPK, AMP-activated protein kinase; HO-1, heme oxygenase-1; PPARγ, proliferator-activated receptor gamma; SOD, serum superoxide dismutase; ROS, reactive oxygen species; ROS, reactive oxygen species; AAK-2, a homolog of adenosine monophosphate (AMP)–activated protein kinase; SKN-1, a homolog of nuclear factor–erythroid 2 related factor 2; MPO, inflammatory cell infiltration, myeloperoxidase.